News Release: One Breath at a Time - Optimizing Access to Care for Patients with Idiopathic Pulmonary Fibrosis
The Institute of Health Economics (IHE), in partnership with the Canadian Foundation for Pulmonary Fibrosis (CPFF) and supported by an unrestricted grant from Boehringer Ingelheim (Canada) Ltd. (BI), held a national, multi-stakeholder roundtable to discuss policy recommendations on idiopathic pulmonary fibrosis (IPF) care.
Today, a group of 30-40 societal representatives, including policy-makers and health system administrators, experts in technology assessment, as well as patients, formal and informal care providers, gathered in Toronto, Ontario, to discuss draft evidence-informed policy recommendations on idiopathic pulmonary fibrosis (IPF).
IPF is a terminal, chronic respiratory disease, characterized by the building of scar tissue in the lungs that can lead to oxygen deprivation to the main organs in the body, causing significant loss of health-related quality of life and early death. IPF patients warrant special considerations for healthcare policy-making due to the low number of identifiable people diagnosed with illness (~14,000 Canadians) and due to the severity of the disease and lack of available treatment options (50% of patients die, usually from lung failure, between two and five years from the time of diagnosis).
“Bringing policy-makers, researchers, clinicians, and patients together will help generate the new solutions required to manage and treat this devastating disease – as breathing should never be hard work.” – Robert Davidson, President, Canadian Pulmonary Fibrosis Foundation.
“Unlike other similarly debilitating diseases, there may be less awareness of the severity of IPF, as well as available resources to support these patients. This roundtable serves to connect the gaps in IPF care – to encourage effective integrated care, while reducing the unnecessary utilization of services and resources, and creating a platform for standardized approaches to treatment.” – Don Husereau, Senior Associate, Institute of Health Economics.
This roundtable is in follow-up to a consensus discussion that took place October 2015.
In October 2015 IHE, in partnership with BI, held the first Canadian consensus discussion that led to provisional recommendations regarding special considerations for policy-making and healthcare decision-making for interventions in patients with IPF. In attendance were representatives of patients, informal caregivers, and physician care providers.
“This roundtable offers a real opportunity to bring together multiple stakeholders involved in the treatment of IPF to work towards the development of much needed policy recommendations in this area. We are pleased to partner with the Institute of Health Economics and the Canadian Pulmonary Fibrosis Foundation as we work together towards our ultimate goal of improving the quality of care for IPF patients,” said Richard Mole, President and CEO, Boehringer Ingelheim (Canada) Ltd.
A summary of key points will be created, under Chatham House rule, including final IPF policy recommendations, for distribution in spring 2016.
Don Husereau, Institute of Health Economics
office: (780) 448-4881
email: [email protected]
Jasmine Brown, Institute of Health Economics
office: (780) 448-4881 | cell: (780) 966-4879
email: [email protected]
For more information about the related discussion please visit the following webpage: